Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963026 | 1.00 | SYK (0.50) | SYKMRGPRX4NPC1RAB9AS1PR4 | |
| SCHEMBL6068795 | 0.86 | MRGPRX4 (0.48) | SYKMRGPRX4NPC1RAB9ALMNA | |
| SCHEMBL8288272 | 0.86 | MRGPRX4 (0.64) | MRGPRX4NPC1S1PR4LMNAGAA | |
| SCHEMBL10227870 | 0.86 | MRGPRX4 (0.53) | SYKMRGPRX4NPC1RAB9AS1PR4 | |
| SCHEMBL29963407 | 0.84 | SYK (0.48) | SYKMRGPRX4NPC1RAB9AS1PR4 | |
| SCHEMBL4411432 | 0.83 | MRGPRX4 (0.48) | SYKMRGPRX4NPC1S1PR4FFAR1 | |
| SCHEMBL21835341 | 0.83 | SYK (0.50) | SYKMRGPRX4S1PR4EGFRERBB2 | |
| SCHEMBL8308367 | 0.83 | SYK (0.46) | SYKMRGPRX4NPC1RAB9ALMNA | |
| SCHEMBL2249164 | 0.82 | MRGPRX4 (0.39) | SYKMRGPRX4NPC1RAB9AFFAR1 | |
| SCHEMBL15701539 | 0.81 | MRGPRX4 (0.53) | MRGPRX4NPC1RAB9AS1PR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246934-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2024-07-25 | — | — | US | disclosed |
| EP-4293016-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2022194265-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | 北京赛特明强医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-1699798-A4 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-2001890-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Bayer HealthCare AG (DE) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| EP-1799653-A2 | NOVEL HETEROCYCLES | Bayer Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1699798-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| WO-2006023843-A2 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005065266-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | SYK 102/4885MRGPRX4 3359/4885NPC1 4309/4885 |
| US-20240246934-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | ABL1, ERBB2, EGFR | SYK 678/4885MRGPRX4 2674/4885NPC1 2980/4885 |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | SYK 415/4885MRGPRX4 1455/4885NPC1 3067/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | SYK 102/4885MRGPRX4 3359/4885NPC1 4309/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | SYK 102/4885MRGPRX4 3359/4885NPC1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.